Clinical Trials Logo

Malignant Primary Brain Tumors clinical trials

View clinical trials related to Malignant Primary Brain Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT04396717 Recruiting - Clinical trials for Brain Metastases, Adult

Safety Study of Pritumumab in Brain Cancer

Start date: March 18, 2021
Phase: Phase 1
Study type: Interventional

Pritumumab is a human IgG1 kappa antibody that binds to a malignant tumor associated antigen, ecto domain-vimentin (EDV) which is expressed in a variety of tumor cells. Pritumumab was shown to have relatively high reactivity with brain cancer cell lines, while no reactivity was demonstrated with normal neurons, astrocytes or fetal cerebral cells. Pritumumab has notable antibody-dependent cellular cytotoxicity (ADCC), brain tumor penetration and antitumor activity in nude mouse human xenograft models. Primary Objectives - To determine the safety and/or tolerability and the recommended Phase 2 dose (RP2D) of escalating, intravenously (IV) administered Pritumumab doses in patients with recurrent gliomas or with brain metastases. Secondary Objectives - To determine pharmacokinetics and pharmacodynamics of Pritumumab - To identify preliminary signals of anti-tumor response to Pritumumab - To explore disease-related, patient-reported outcomes

NCT ID: NCT01100658 Terminated - Brain Tumors Clinical Trials

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

Start date: May 2010
Phase: N/A
Study type: Interventional

While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention deficits in this population. Numerous studies have examined the effectiveness of methylphenidate in the treatment of children with attention deficit hyperactivity disorder (ADHD). However, the effectiveness of this medication for improving attention and behavioral functioning in children with medical illnesses or brain injury are less clear. Patients will be randomized to receive one week of Metadate CD (a controlled release form of methylphenidate, similar to Ritalin) and one week of placebo in a double-blind fashion.